Importance of Bevacizumab Maintenance Following Combination Chemotherapy in Human Non–small Cell Lung Cancer Xenograft Models

Autor: Mariko Noguchi-Sasaki, Mitsue Kurasawa, Kaname Yamamoto, Masamichi Sugimoto, Keigo Yorozu, Nobuyuki Ishikura, Toshiki Iwai, Mieko Yanagisawa
Rok vydání: 2017
Předmět:
Male
Oncology
Cancer Research
medicine.medical_specialty
Lung Neoplasms
genetic structures
Bevacizumab
Mice
Nude
Pemetrexed
Thymidylate synthase
Maintenance Chemotherapy
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Maintenance therapy
Carcinoma
Non-Small-Cell Lung
Cell Line
Tumor
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
medicine
Animals
Humans
Lung cancer
Mice
Inbred BALB C
Neovascularization
Pathologic
biology
business.industry
Standard treatment
Combination chemotherapy
Induction Chemotherapy
General Medicine
medicine.disease
Xenograft Model Antitumor Assays
eye diseases
Tumor Burden
Paclitaxel
chemistry
A549 Cells
030220 oncology & carcinogenesis
biology.protein
sense organs
business
030217 neurology & neurosurgery
medicine.drug
Zdroj: Anticancer Research. 37:623-630
ISSN: 1791-7530
0250-7005
DOI: 10.21873/anticanres.11356
Popis: Background Bevacizumab in combination with chemotherapeutics has shown significant survival benefit in clinical studies in patients with non-small cell lung cancer (NSCLC). Since bevacizumab was administered as standard treatment until disease progression, the importance of bevacizumab during the maintenance phase was not prospectively investigated in these studies. Materials and methods Three human NSCLC cell line xenograft models were used to investigate antitumor effect of bevacizumab and tumor microvessel density (MVD) was analyzed. Results In A549 and NCI-H292 models, bevacizumab maintenance following combination with paclitaxel exhibited stronger tumor suppression than its absence. In an NCI-H292 model, bevacizumab maintenance continuously inhibited increase of MVD. In an NCI-H2228 model following induction treatment with pemetrexed and bevacizumab, maintenance with pemetrexed plus bevacizumab, had stronger efficacy than pemetrexed alone and led to lower MVD and level of thymidylate synthase. Conclusion Continuous suppression of angiogenesis by bevacizumab may contribute to the superior efficacy of maintenance treatment containing bevacizumab.
Databáze: OpenAIRE
Externí odkaz: